[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors (scientific article)

Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

Q48588059

Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats

Q48654467

A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes

Q48793567

AF150(S): A new functionally selective M1 agonist improves cognitive performance in rats

Q48799211

Simplified reference tissue model for PET receptor studies.

Q48832665

Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study

Q48873627

Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.

Q48985494

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

Q52168809

Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats.

Q52170510

Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET

Q57089247

Two affinity states of M1 muscarine receptors

Q68484517

Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist

Q72203819

Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET.

Q31911220

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

Q33175130

On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis

Q33421837

A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum

Q33861946

AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease

Q34147757

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

Q34212336

Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain

Q34253793

PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man.

Q34400131

G protein-coupled receptor allosterism and complexing

Q34523552

Importance and prospects for design of selective muscarinic agonists

Q34778777

Muscarinic receptors as a target for drugs treating schizophrenia

Q35137416

Molecular Mechanisms of Bone 18F-NaF Deposition

Q35203602

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

Q35205922

Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data.

Q36700008

Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease

Q37961834

Muscarinic receptors--characterization, coupling and function

Q40384205

Receptor subtypes or species homologues: relevance to drug discovery

Q40808688

5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade

Q41197529

Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain

Q41538057

Reproducible Analysis of Rat Brain PET Studies Using an Additional [(18)F]NaF Scan and an MR-Based ROI Template

Q42183322

Reconstitution of agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11, and phospholipase C-beta 1

Q43508385

Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists

Q43651491

In vivo visualization of central muscarinic receptors using [11C]quinuclidinyl benzilate and positron emission tomography in baboons

Q43962571

Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine.

Q44489489

Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice

Q44521481

Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist, (R,S)-5-hydroxy-2-(N-propyl-N-(5'-(18)F-fluoropentyl)aminotetralin ((18)F-5-OH-FPPAT) in rodents and nonhuman primates

Q44803575

M1 muscarinic antagonists interact with sigma recognition sites

Q44918686

Binding characteristics of high-affinity dopamine D2/D3 receptor agonists, 11C-PPHT and 11C-ZYY-339 in rodents and imaging in non-human primates by PET.

Q45047807

Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors

Q45228605

Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice

Q45231582

Accuracy of 3-dimensional reconstruction algorithms for the high-resolution research tomograph

Q46192833

A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey

Q46476544

Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.

Q46534517

In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment

Q46713725

Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride

Q46896544

Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner

Q48272311

Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain

Q48291672

Imaging opiate receptors in the human brain by positron tomography

issue

page(s)

publication date

2013-03-21

P1433

published in

EJNMMI Research

Q27723773

P1476

title

[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

P478

volume

Reverse relations

cites work (P2860)

Q26865012	Application of cross-species PET imaging to assess neurotransmitter release in brain
Q38788038	Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
Q93204051	Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging
Q52593214	In vitro pharmacological characterization and in vivo validation of LSN3172176 a novel M1 selective muscarinic receptor agonist tracer molecule for positron emission tomography (PET).
Q61455308	Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics
Q48176913	News and views on in-vivo imaging of neurotransmission using PET and MRI.
Q38531787	Optimising PET approaches to measuring 5-HT release in human brain
Q42354388	[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats